California imposes some of the most aggressive prescription drug coverage mandates in the country, and fully-insured employers pay for every one of them. Self-funded ERISA plans are largely exempt, and that exemption has real dollar implications.
Here's what's broken. Between 2017 and 2024, prescription drug costs increased 70.4% for DMHC-regulated health plans in California, according to the California Health Benefits Review Program's SB 1199 Technical Brief. Fully-insured employers absorbed that trend through their premiums. Self-funded employers mostly didn't.
That's not an accident. That's structure.
Key takeaways
California fully-insured plans paid $14.9 billion for prescription drugs in 2024, up 9.5% from the prior year, equal to 12.1% of total plan premiums.
State mandates on formulary design and cost-sharing apply to DMHC- and CDI-regulated plans. Self-funded ERISA plans are generally preempted from these requirements.
Under current California law, enrollee cost-sharing for prescription drugs in most regulated plans is capped at $250 per drug, or $500 for Covered California bronze plans.
SB 1199, active as of July 2026, proposes further cost-sharing caps and was amended in July 2026 to align with federal HDHP rules.
Specialty drugs are only 1.8% of prescriptions dispensed but drive a disproportionate share of total spend, making formulary design a high-impact decision.
Self-funded employers who move off fully-insured carriers gain control over formulary design that state mandates would otherwise restrict.
What does California actually require for prescription drug coverage?
California's mandates for prescription drug coverage apply to plans regulated by the Department of Managed Health Care (DMHC) or the California Department of Insurance (CDI). Fully-insured group plans fall under this umbrella. Under existing California law (Health and Safety Code 1342.73 and Insurance Code 10123.1932), cost-sharing for prescription drugs in most regulated plans is capped at $250 per drug, with a $500 cap for enrollees in Covered California bronze plans, according to the CHBRP analysis of SB 1094.
That sounds like consumer protection. For employers, it limits how plan design can shift cost to members, which affects total plan spend. You can't build a high-cost-sharing formulary tier to discourage overuse of brand drugs when the state has set a ceiling.
California also has PBM-specific rules. A U.S. GAO report cited in the Carelon Rx Q2 2024 State and Federal Regulatory and Legislative Activity Update identified California as one of five states, alongside Arkansas, Louisiana, Maine, and New York, that has enacted PBM laws establishing fiduciary duty-of-care requirements, drug pricing and pharmacy reimbursement rules, transparency and licensure requirements, and pharmacy network and access requirements.
That's a dense regulatory stack sitting on top of your carrier's formulary decisions.
What is SB 1199, and why does it matter for your 2027 renewal?
SB 1199 is active legislation that would further cap prescription drug cost-sharing for DMHC-regulated plans. The CHBRP 2025-2026 Amendments and Analysis Updates show the bill was amended on July 2, 2026 to align language with federal rules related to high-deductible health plans. The amendment also allows copay adjustment programs for branded drugs until an FDA-approved therapeutically equivalent version has been available for three calendar months.
That HDHP alignment matters. California has historically been out of sync with federal HSA eligibility rules, which created compliance headaches for employers trying to offer an HSA-qualified plan. The July 2026 amendment is an attempt to fix that conflict.
If SB 1199 passes, it adds another layer to what fully-insured plans must cover and how much members can be charged. Your carrier bakes that into premiums. You pay it at renewal, usually without a line-item explanation.
Where does the $14.9 billion actually go?
In 2024, DMHC-regulated health plans in California paid approximately $14.9 billion for prescription drugs, a 9.5% increase ($1.3 billion) from the prior year, representing 12.1% of total DMHC-regulated health plan premiums. Those numbers come directly from the CHBRP SB 1199 Technical Brief.
Specialty drugs drove the disproportionate share of that spend. They accounted for only 1.8% of all prescriptions dispensed, yet their cost concentration is severe. One percent of utilization can represent 40% or more of total drug cost.
Before you keep reading
Get the next one in your inbox.
Analysis like this, every other Wednesday. Written for the person who signs the renewal.
Subscribe and get the PBM Renegotiation Checklist. Free PDF.
Every other Wednesday. Unsubscribe anytime. We may show your company’s logo on our homepage. Privacy
California's mandate structure doesn't give fully-insured employers many tools to manage that concentration. Formulary tiers, prior authorization protocols, and step therapy requirements are all subject to state override rules. Self-funded plans don't face those constraints in the same way.
Want to know why the specialty drug pipeline keeps showing up in your renewal conversation? That 1.8% figure is your answer.
How does ERISA preemption change the math for self-funded employers?
ERISA preempts state insurance mandates for self-funded employer plans. That's not a loophole. It's federal law. A self-funded employer in California isn't bound by the $250 per-drug cost-sharing cap, the PBM fiduciary rules that California imposes on carriers, or the formulary restrictions tied to SB 1199.
That freedom translates directly into plan design options. A self-funded employer can build formulary tiers that create meaningful cost-sharing differences between brand and generic drugs. They can implement step therapy without state approval. They can contract directly with a PBM and set terms that a carrier would never agree to on a fully-insured basis.
The math is straightforward. Every mandate California adds to DMHC-regulated plans increases premium for fully-insured employers. Self-funded employers building a compliant ERISA plan don't absorb those costs automatically. They choose what to cover, and they see the numbers.
What should a California employer actually do with this information?
First, know which regulatory bucket you're in. If you're fully insured, your plan is subject to every mandate described above. If you're self-funded, you have options your carrier has never offered to explain.
Second, ask your broker for a self-funding feasibility analysis. Groups as small as 50 enrolled lives can self-fund successfully with the right stop-loss structure. The break-even isn't always obvious from the surface premium comparison.
Third, don't wait for SB 1199 to finalize. Employers who move before a mandate layers in avoid the cost. Employers who wait pay the new baseline and then try to work backwards.
Frequently asked questions
Does ERISA preemption mean a self-funded California employer has zero state compliance obligations?
No. ERISA preempts state insurance mandates, but self-funded plans still comply with federal law, including ERISA itself, ACA market reforms that apply to all group health plans, HIPAA, and the Mental Health Parity and Addiction Equity Act. California can't dictate formulary design or cost-sharing caps to a self-funded ERISA plan, but federal rules still govern the plan's structure and administration.
What is the $250 per-drug cost-sharing cap and who does it apply to?
Under California Health and Safety Code 1342.73 and Insurance Code 10123.1932, enrollee cost-sharing for any single prescription drug is capped at $250 per drug in most DMHC- and CDI-regulated plans. Covered California bronze plan enrollees face a $500 cap instead. The rule applies to fully-insured group and individual plans regulated by those agencies. Self-funded ERISA plans aren't subject to this cap.
When would SB 1199 take effect, and does it apply to self-funded plans?
SB 1199 is active legislation as of July 2026 and has not yet been enacted into final law. If passed, it would apply to DMHC-regulated plans, not to self-funded ERISA plans. The July 2, 2026 amendment added language to align the bill with federal HDHP and HSA eligibility rules, which had been a significant compliance conflict in prior versions.
Why do specialty drugs matter so much to overall plan cost?
Specialty drugs represented only 1.8% of all prescriptions dispensed in California's DMHC-regulated plans in 2024, but they drove a disproportionate share of the $14.9 billion in total drug spend. High per-unit costs combined with growing utilization for conditions like autoimmune disease, oncology, and rare diseases make specialty drugs the single highest-impact category in most employer pharmacy budgets. Formulary management for specialty drugs is where plan design decisions produce the largest dollar swings.
Can a small employer in California self-fund its health plan?
Yes. Groups as small as 50 enrolled lives regularly self-fund with stop-loss coverage in place to cap catastrophic claims. Stop-loss insurance, purchased from a carrier separate from the health plan, reimburses the employer when individual claims or aggregate annual claims exceed agreed thresholds. The feasibility depends on group size, claims history, and risk tolerance, not on California law, which can't prohibit self-funding under ERISA.
